Abbott rises after continuous glucose monitor reduce hospitalizations

Shares of medical device maker Abbott Laboratories ABT.N up 1.8% at $130.92

ABT says its study of a continuous glucose monitoring (CGM) device called FreeStyle Libre showed a 78% reduction in the risk of hospitalization for heart-related issues in people with diabetes

Co says the study of the device was conducted using data from the Swedish National Diabetes Register

Co says significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors

Libre technology is used for patients to see their real-time glucose numbers, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals

Including session's moves, stock up 15.3% YTD